A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price target on shares of Insulet from $399.00 to $375.00 and set a "buy" rating on the stock in a research report on Wednesday, October 1st. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Finally, Zacks Research raised shares of Insulet from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company.